STI/HIV | Men (N=285) | Women (N=313) | p Value* | Total (N=598) |
n (%) | n (%) | % (95% CI) | ||
Neisseria gonorrhoeae | 3 (1.1) | 1 (0.3) | 0.27† | 0.7 (0.2 to 1.7) |
Chlamydia trachomatis | 4 (1.4) | 15 (4.8) | 0.02 | 3.2 (1.9 to 4.9) |
High-risk HPV | 41 (14.4) | 75 (24.0) | 0.003 | 19.4 (16.3 to 22.8) |
Syphilis exposure (FTA-ABs+)‡ | 10 (3.6) | 8 (2.6) | 0.51 | 3.1 (1.8 to 4.8) |
Active syphilis (FTA-ABs+/VDRL+)§ | 9 (3.2) | 8 (2.6) | 0.70 | 2.8 (1.7 to 4.5) |
Serological HSV-2 | 143 (51.1) | 220 (72.1) | <0.001 | 62.1 (58.0 to 66.0) |
Serological HBV (anti-HBc)¶ | 106 (37.9) | 130 (42.6) | 0.24 | 40.3 (36.3 to 44.4) |
Serological HBV (HBsAg)** | 21 (7.5) | 14 (4.6) | 0.14 | 5.9 (4.0 to 7.9) |
Serological HCV | 2 (0.7) | 2 (0.7) | 0.90† | 0.7 (0.2 to 1.7) |
Serological HIV | 4 (1.4) | 0 (0.0) | 0.04† | 0.7 (0.2 to 1.7) |
↵* Using Pearson χ2 test unless specified.
↵† Fisher's exact test.
↵‡ FTA-ABs with a positive result.
↵§ FTA-ABs with a positive result confirmed by VDRL.
↵¶ Markers of chronic HBV infection.
↵** Markers of active HBV infection.
FTA-ABs, fluorescent treponemal antibody absorption; HBV, hepatitis B virus; HCV, hepatitis C virus; HPV, human papillomavirus; HSV-2, herpes simplex virus type-2; STI, sexually transmitted infection; VDRL, Venereal Diseases Research Laboratory.
Bold values indicate statistical significance (p<0.05).